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Abstract
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a new drug class designed to treat patients with type 2 diabetes (T2D).
However, cardiovascular outcome trials showed that SGLT2i also offer protection against heart failure (HF)–related events and
cardiovascular mortality. These benefits appear to be independent of glycaemic control and have recently been demonstrated in
the HF population with reduced ejection fraction (HFrEF), with or without T2D. This comprehensive, evidence-based review
focuses on the published studies concerning HF outcomes with SGLT2i, discussing issues that may underlie the different results,
along with the impact of these new drugs in clinical practice. The potential translational mechanisms behind SGLT2i cardio-renal
benefits and the information that ongoing studies may add to the already existing body of evidence are also reviewed. Finally, we
focus on practical management issues regarding SGLT2i use in association with other T2D and HFrEF common pharmacological
therapies. Safety considerations are also highlighted. Considering the paradigm shift in T2D management, from a focus on
glycaemic control to a broader approach on cardiovascular protection and event reduction, including the potential for wide
SGLT2i implementation in HF patients, with or without T2D, we are facing a promising time for major changes in the global
management of cardiovascular disease.
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Diabetes and Heart Failure
Type 2 diabetes (T2D) and heart failure (HF) are common and
often coexisting conditions, with a harmful relationship. HF
affects at least 26 million people worldwide, but projections
regarding rising prevalence for the next decades are alarming,
namely due to an ageing population and to the expected in-
crease in HF with preserved ejection fraction (HFpEF) [1–5].
Currently, despite advances in HF treatment, mortality can
reach 50% at five years, exceeding that observed in most
common malignant neoplasms [6, 7]. Hospitalizations con-
tribute to the high morbidity in HF and account for most of
its costs, which are likely to rise dramatically [3, 4, 8].
The prevalence of T2D has nearly doubled since 1980 and
is expected to affect nearly 580 million individuals worldwide
in 10 years, and 700 million by 2045 [9, 10]. T2D is a major
risk factor for the development of cardiovascular disease
(CVD), its main cause of morbidity and mortality [11, 12].
The relationship between T2D and HF has been well
established since the Framingham study, which reported a 2-
and 5-fold higher risk of HF in men and women with T2D,
respectively, compared with individuals without T2D [13].
More recently, the Reykjavik study described a 12% preva-
lence of HF in the T2D population vs. 3% in individuals
without T2D [14].
T2D is associated with cardiac structural changes in-
cluding increased interstitial fibrosis, left ventricular hy-
pertrophy, endothelial dysfunction, microangiopathic pro-
cesses and inflammation, factors that confer a higher risk
for developing HF with or without a reduced ejection
fraction (rEF) [15]. T2D adversely affects outcomes
amongst patients with HF, has a substantial influence on
the costs of managing HF patients, extends hospital stay
and worsens prognosis [4, 16]. On the other hand, HF
increases the risk of fatal and non-fatal cardiovascular
(CV) events in T2D patients [17].
Sodium-glucose co-transporter 2 inhibitors (SGLT2i)
have emerged as a new class of drugs designed to treat
patients with T2D, but have also been shown to be pro-
tective against HF-related events and CV mortality.
Herein, we present a comprehensive, evidence-based
overview concerning the use of SGLT2i in patients with
or without T2D at risk for CV events, focusing on HF
outcomes. Additionally, we perform a critical analysis of
the SGLT2i cardiovascular outcome trials (CVOTs) and
discuss the SGLT2i possible translational mechanisms
behind the clinical outcomes, with an overview of the
ongoing SGLT2i functional capacity, mechanistic and
HF outcomes trials. Finally, we present a summary of
practical considerations regarding the co-administration
of SGLT2i and common therapies used in T2D and
HFrEF, as well as management of safety issues, based
on expert opinion and current recommendations.
Improving Prognosis: the Clinical Research
Arena
SGLT2i Cardiovascular Outcome Trials in T2D Patients
Due to concerns for possible adverse CVoutcomes with anti-
diabetic agents, both the Food and Drug Administration
(FDA) and the European Medicines Agency require that all
new glucose-lowering drugs demonstrate CV safety in T2D
patients. This is now tested in CVOTs that analyse drug safety
in terms of MACE (major adverse cardiovascular events),
which include CV death, non-fatal myocardial infarction
(MI) and non-fatal stroke (3-point MACE). Surprisingly, HF
outcomes, which can be precipitated by some antidiabetic
drugs [18], are not included as a mandatory component of
composite endpoints [19].
A paradigm shift in T2D management emerged when
CVOTs with SGLT2i [20–22] demonstrated that these drugs
are not only safe in terms of 3-point MACE but may also be
beneficial in HF-related and renal events, regardless of the
presence of atherosclerotic CVD (ASCVD) or HF at baseline.
The EMPA-REG OUTCOME Trial
The EMPA-REG OUTCOME trial analysed the outcomes of
the SGLT2i empagliflozin vs. placebo in patients with T2D
and established CVD at baseline, and demonstrated the supe-
riority of empagliflozin in reducing the risk of 3-point MACE,
with significant reductions in CV death, all-cause death and in
hospitalization for HF (HHF). Observed benefits were related
to a decrease in incident HF events rather than to prevention of
ischemic CV events [20]. These unexpected results led
empagliflozin to become the first glucose-lowering drug ap-
proved for CV death protection in T2D patients.
Post hoc analyses of the EMPA-REG OUTCOME trial
revealed that besides the higher incident rates of HHF, CV
death and all-cause mortality in patients with HF at baseline
compared with patients without HF, the risk reductions of
these outcomes with empagliflozin were consistent in both
subgroups (hazard ratio (HR): 0.67, 95% confidence interval
(CI) 0.47–0.97 in patients with HF burden (defined as HF at
baseline, HHF or incident HF without hospitalization during
the trial); HR 0.63, 95% CI 0.48–0.84 in patients without HF
burden) [23]. The observed benefit with empagliflozin ex-
tends to the two causes of cardiac death in HF: sudden death
and pump failure [24].
The CANVAS Program and the DECLARE-TIMI 58 Trial
The CANVAS program [21], which included the CANVAS
and CANVAS-R (renal) studies, assessed the CV safety and
efficacy of canagliflozin in patients with T2DM and
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































DECLARE-TIMI 58 trial [25] compared dapagliflozin vs.
placebo in patients with T2DM with either established
ASCVD or multiple risk factors for ASCVD. These trials
showed that both SGLT2i also reduced the composite end-
point of CV death and HHF in T2D patients, with similar
results observed with dapagliflozin for patients with and with-
out HF at baseline [22]. The results for both trials were driven
by a reduction in HHF, with no significant reduction in CV
death alone.
Table 1 presents a summary of the CVOTs with SGLT2i.
These CVOTs have different designs and inclusion criteria,
and therefore are difficult to compare; additionally, the defini-
tion of CV risk is variable across studies, and there is no
information regarding baseline LV ejection fraction (LVEF).
Meta-analyses
A question that remains unresolved is whether the effects are
consistent across the SGLT2i class, or whether pharmacologic
differences between the drugs may translate into differences in
clinical efficacy and safety outcomes.
Two meta-analyses on SGLT2i CVOTs have been recently
published, aiming to better estimate the class effect of these
drugs on CV outcomes [27, 28]. The most recent meta-
analysis showed a consistent class effect of SGLT2i in reduc-
ing HHF in patients with or without baseline CVD, as well as
a consistent effect on preventing the progression of renal dis-
ease [27].
Overall, SGLT2i reduced the risk of MI by 11% and the
risk of CV death by 16%, although significant heterogeneity
in CV death was observed between trials. Similarly, all-cause
mortality was reduced by 15%, again with significant hetero-
geneity. When only patients with ASCVD were compared
within trials (excluding patients with multiple CV risk factors
in the CANVAS and DECLARE-TIMI 58 trials) ,
empagliflozin was the only that showed significant reductions
on CV death and all-cause mortality. Similarly, an increased
risk in amputations and fractures was only noted with
canagliflozin [27].
It is possible that either pharmacologic differences within
the class, or differences in the baseline risk within the study
populations, may be responsible for the observed heterogene-
ity in mortality outcomes. The consistently higher event rates
in the placebo group in EMPA-REG (compared with the pla-
cebo arms in CANVAS and DECLARE-TIMI 58) reflect a
higher risk population in the former (also when comparing
the ASCVD groups only), which might account for the differ-
ences observed between trials.
The estimated glomerular filtration rate (eGFR) cut-off for
EMPA-REG was less restrictive, thus allowing for patients
with more severe renal dysfunction to be included in the trial.
The percentage of patients with eGFR < 60 mL/min was
25.9% in EMPA-REG compared with 20.1% in CANVAS
and 7.4% in DECLARE-TIMI 58. Nonetheless, in a
subanalysis conducted to determine the impact of eGFR on
CV death in EMPA-REG, a consistent effect on CV mortality
was observed, independent of baseline eGFR [20, 29, 30].
Furthermore, the recent CREDENCE trial tested
canagliflozin vs. placebo in 4200 T2D patients with nephrop-
athy, an eGFR of 30 to < 90 mL/min and albuminuria [31].
Over 50% of the population had established CVD, and 14.8%
had HF at baseline. During a median follow-up of 2.62 years,
canagliflozin did not significantly reduce CV death alone,
despite a nominally non-significant p value (HR 0.78, 95%
CI 0.61–1.00, p = 0.05), or all-cause death ((HR 0.83, 95% CI
0.68–1.02, p = not available (NA)), but showed a pronounced
reduction in HHF (HR 0.61, 95% CI 0.47–0.80, p < 0.001).
In aggregate, these findings suggest that in patients with
greater renal dysfunction, SGLT2i confer even higher reduc-
tions in HHF, as also suggested by the meta-analysis results
[27]. However, the degree of renal dysfunction or presence of
established CVD does not appear to fully explain the observed
heterogeneity in terms of mortality amongst the three pub-
lished SGLT2i CVOTs.
Based on this heterogeneity, the 2019 European Society of
Cardiology (ESC) Guidelines [32] on diabetes, pre-diabetes
and CVD, developed in collaboration with the European
Association for the Study of Diabetes (EASD), has given
empagliflozin a class IB recommendation to reduce the risk
of death in patients with T2D and CVD. In addition,
empagliflozin, dapagliflozin and canagliflozin are recom-
mended in patients with T2D and CVD or at very high/high
CV risk, to reduce CVevents, as first-line antidiabetic therapy
in naive patients, not previously treated with metformin [32].
This recommendation is criticized, namely by the convincing
beneficial effects (HbA1c 6.5–7.5%) (glycated haemoglobin)
of early combination therapy [33].
A CVOT with the SGLT2i ertugliflozin [26] is currently
underway, with results expected in the near future (Table 1).
SGLT2i Effects on HF Outcomes in T2D Patients
Additional subanalyses of the three abovementioned CVOTs
[20–22] have been published, revealing further data
concerning SGLT2i effects on HF outcomes in patients with
T2D.
An analysis of the CANVAS program showed that
canagliflozin reduced the overall risk of HF events in patients
with T2D and high CV risk, with no clear difference in effects
on HFrEF vs. HFpEF events [34].
A recent analysis of the DECLARE-TIMI 58 trial investi-
gated the efficacy of dapagliflozin in T2D patients considering
baseline HF status [25]. In patients with T2D and baseline
HFrEF, dapagliflozin reduced HHF, CV death and all-cause
mortality, whereas in patients with T2D without baseline
HFrEF, the only reduction observed was in HHF [25].
Cardiovasc Drugs Ther
SGLT2i HF-Dedicated Outcomes Trials in Patients
with or without T2D
More recently, the DAPA-HF trial results were published [35].
The trial included 4744 HFrEF patients with our without T2D
followed over a median of 18.2 months. It was demonstrated
that dapagliflozin 10 mg daily significantly reduced the pri-
mary composite endpoint of worsening HF (including HHF or
urgent HF visits) and CV death in a population highly treated
with background disease-modifying HF therapies (HR 0.74,
95% CI 0.65–0.85, p = 0.001), either in patients with (HR
0.75, 95% CI 0.63–0.90, p = NA) or without diabetes (HR
0.73, 95% CI 0.60–0.88, p = NA) [36]. The number of pa-
tients needed to treat (NNT) with dapagliflozin to prevent
one primary event during the trial duration was 21 (95% CI
15–38). Importantly, in a post hoc analysis including patients
on concomitant sacubitril/valsartan therapy at baseline (nearly
10% of the trial population), the HR for the primary outcome
was consistent amongst patients on- or off-sacubitril/valsartan.
Despite the low percentage of patients treated with sacubitril/
valsartan at baseline, it appears that the benefits of SGLT2i
therapy are additive to those afforded by neurohormonal mod-
ulating agents. Moreover, possible heterogeneity was ob-
served according to New York Heart Association (NYHA)
functional class, showing greater treatment benefit in class II
patients, compared with class III or IV [35]. Regarding safety,
the occurrence of adverse events (AEs) was low and similar
between dapagliflozin and placebo, except for significantly
more severe renal adverse events (AEs) in the placebo group
(2.7% vs. 1.6%, p = 0.009) [36].
Table 2 and Table 3 summarize the ongoing HF-dedicated
outcomes [36–38] and functional capacity clinical trials with
SGLT2i, which will enhance the body of evidence for these
agents in HF populations.
From Clinical Trials to the Real World
The SGLT2i positive impact on CV outcomes observed in
CVOTs, specifically regarding HHF, was also observed in
the real-world evidence (RWE) studies CVD-REAL and
EMPRISE [41, 42].
CVD-REAL study included 309,056 T2D patients with or
without CVD at baseline, newly treated with SGLT2i or other
glucose-lowering drugs, from registries within six countries.
All primary analyses showed a benefit of SGLT2i over other
glucose-lowering drugs: HHF (HR 0.61, 95% CI 0.51–0.73,
p < 0.001); all-cause mortality (HR 0.49, 95% CI 0.41–0.57,
p < 0.001), and HHF or death by any cause composite out-
come (HR 0.54, 95% CI 0.48–0.60, p < 0.001) [42].
The ongoing EMPRISE study a ims to assess
empagliflozin’s effectiveness, safety, and healthcare utiliza-
tion in routine care in the USA, including data from 232,000
T2D patients newly initiated on empagliflozin or sitagliptin.
After five months follow-up of the nearly 32,000 matched
patients, empagliflozin decreased the risk of HHF by 50%
(HR 0.50, 95% CI 0.28–0.91, p =NA), with consistent results
in patients with or without baseline CVD [41].
The available data on SGLT2i, both from CVOTs and from
RWE, has undoubtedly shifted the paradigm of T2D manage-
ment in clinical practice from a focus on glycaemic control to
a broader approach on CV event reduction, and also as a po-
tential new class of drugs for HF treatment even in people
without T2D. Given the impressive cardioprotective effects
of SGLT2i, the results of the DAPA-HF trial were enthusias-
tically received. Results of other ongoing trials with SGLT2i
in high-risk diabetic and non-diabetic cardiovascular popula-
tions are keenly awaited and should shed more light into pos-
sible differences in clinical outcomes and prognosis, most
importantly in mortality and on potential beneficial effect on
MI, which remains an active topic of investigation [27, 43].
Potential Mechanisms
Behind the Cardio-renal Benefits Observed
with SGLT2i
Although impressive results have been achieved with
SGLT2i, there is a lack of knowledge of the mechanisms as-
sociated with the observed benefits.
SGLT2i inhibit glucose and sodium reabsorption in the
kidneys, thus resulting in glycosuria. Their effects conse-
quently include reductions in HbA1c, blood glucose levels
and blood pressure (BP), but also reductions in body weight
and adiposity, all mechanisms that may contribute to reducing
cardiovascular risk and HF [27, 44]. The reduction in systolic
and diastolic BP is reported to be about 3–7 and 2 mmHg,
respectively, and seems to be independent of disease status or
treatment with antihypertensive drugs [45]. Also, a reduction
in body weight is consistently observed in individuals taking
SGLT2i, but the magnitude of weight loss is modest (1 to
3 kg) both in T2D and in obese patients without diabetes,
due to counter-regulatory mechanisms striving to maintain
body weight. It is unknown whether such effects can translate
into reduced cardiovascular disease events, including HF [45].
However, the evidence indicates that the cardioprotective
benefits behind SLGT2i go beyond roles in glycemia, BP
control, and weight loss. Firstly, the glucose and BP-
lowering effects of SGLT2i compared with placebo are not
sufficient to explain the outcomes observed in randomized
clinical trials (RCT). Secondly, if the beneficial effects of
SGLT2i were due exclusively to glycaemic or BP control,
these effects should impact all CV outcomes. Although
SGLT2i have a significant effect on the prevention of HF
events, they are neutral in preventing atherothrombotic events

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































subanalysis from DECLARE-TIMI 58 suggested a reduction
in type 2 MI, possibly by ischemic and not anti-thrombotic
mechanisms [27, 43]. Additionally, the beneficial effects of
SLGT2is are seen at similar proportions across patients with
different levels of HbA1c and eGFR.
Several hypotheses have thus been postulated to explain
the cardio-renal outcomes observed with SLGT2i, beyond
effects on glycemia, BP and weight loss (Fig. 1).
The “Super Fuel” Hypothesis
The healthy myocardium is metabolically “omnivorous” and
able to switch between different sources of energy; it can use
carbohydrates, ketones, lactate and certain amino acids as fuel,
but utilizes preferentially free fatty acids (FFA) for energy
production, which yield substantial amounts of energy in the
form of adenosine triphosphate (ATP) molecules, albeit at the
expense of higher oxygen consumption [47]. Ketone bodies
may also be used by the myocardium as the most energy-
efficient fuel source, producing the largest number of ATP
molecules at the lowest oxygen expense.
In the diseasedmyocardium, there is an increased uptake of
glucose and FFA into the cytosol, but this becomes uncoupled
from their uptake and oxidation in the mitochondria, leading
to an accumulation of metabolic intermediates, ultimately
resulting in toxicity [48]. In patients treated with
empagliflozin the induced glycosuria results in lower plasma
glucose and insulin levels, with concomitant increased plasma
glucagon (resembling a fasting state), leading to enhanced
lipid mobilization [49, 50]. The lower ratio of insulin/
glucagon at the portal vein and the increased circulation of
FFA stimulate ketogenesis in the liver [51].
This hypothesis, suggested by previous authors as the
“thrifty substrate” hypothesis, postulates that SGLT2i cause
a mild but persistent increase in the production of ketone bod-
ies, in particular beta-hydroxybutyrate, which becomes, along
with FFA, the main substrates for ATP production in the myo-
cardium, in detriment of glucose. Because ketone bodies are
more energy-efficient than FFA, this shift greatly improves the
energetic efficiency of the heart [52] and reduces cytotoxicity
[48].
Although animal studies have been conducted to test
this hypothesis, it still lacks confirmatory clinical data to
support it. A study in a non-diabetic porcine model sub-
jected to MI showed that empagliflozin increases myocar-
dial consumption of ketones at the same time that it re-
duces glucose consumption, with increased myocardial
energetics leading to reverse remodelling at anatomical,
metabolic and neurohormonal levels [46]. The same in-
vestigators are currently conducting a trial with
empagliflozin (the EMPA-TROPISM study [53]),
attempting to translate these results into the clinical arena.
The Sodium-Hydrogen Exchanger Hypothesis
One alluring hypothesis that has been put forward is that
SLGT2i may offer cardio-renal benefits by directly binding
to and inhibiting the sodium-hydrogen exchangers (NHE) in
the heart and kidney [54]. The NHE1 isoform is ubiquitously
distributed and is the predominant isoform expressed in the
heart [55], whereas NHE3 expression is limited to epithelial
cells of the gut and kidney, being responsible for most of the
sodium reuptake after glomerular filtration [56, 57]. In HF, the
activity of NHE1 in cardiomyocytes is markedly increased,
leading to higher concentrations of Na+ in the cytosol, which
in turn triggers an increase in intracellular Ca2+ and ultimately
lead to cardiomyocyte injury and cardiomyopathy [54].
Experimental models have shown that SLGT2i directly
bind to NHE1 in cardiomyocytes, reducing cytoplasmic Na+
and Ca2+ levels [58–60]. It should be noted that the SLGT2
transporter is not expressed in the heart [61]; thus, SLGT2i
cannot exert their action in cardiomyocytes via SLGT2 inhi-
bition. It has been postulated that SLGT2i may also downreg-
ulate the activity of NH3 in the proximal tubule [62]. Animal
models have shown that NH3 expression is increased in HF as
a result of upregulation of mineralocorticoids, leading to fluid
retention and peripheral oedema [63, 64]. Mineralocorticoid
antagonists such as spironolactone inhibit both NHE1 and
NHE3 and ameliorate experimental models of HF [65–71].
Interestingly, in the EMPA-REG OUTCOME trial, the CV
benefits with empagliflozin were attenuated in patients receiv-
ing spironolactone at baseline [29]. However, the same effect
was not observed in the DAPA-HF trial, where over 70% of
the population received background therapy with aldosterone
antagonists [35].
The “Smart Diuretic” Hypothesis
The “smart diuretic” hypothesis suggests that the favourable
effects observed with SGLT2i are in part due to their more
selective diuretic effects. SGLT2i have unique diuretic prop-
erties whereby they modulate the function of the proximal
tubule, leading to natriuresis, glycosuria and ensuing osmotic
diuresis [72]. The consequent sodium and volume reductions
would result in lower preload and afterload, leading to im-
proved cardiac loading conditions [73]. The proximal tubule
action and natriuretic effect act as stimuli for tubuloglomerular
feedback, resulting in afferent arteriolar vasoconstriction, thus
lowering glomerular hypertension, and likely causing an
antiproteinuric effect [73]. Besides volume contraction,
SGLT 2 i h a v e a l s o b e e n s h ow n t o i n c r e a s e
haemoconcentration, possibly also associated to intrinsic renal
mechanisms, such as the recovery of tubulointerstitial hypoxia
and increased erythropoietin (EPO) production, mechanisms
that require further clarification [74, 75]. It may be hypothe-






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































oxygen delivery to myocardial tissue and serve as a comple-
mentary mechanism to the “super fuel” hypothesis, further
enhancing myocardial efficiency [52]. Furthermore, it has
been proposed that SGLT2i have the ability to selectively
reduce interstitial fluid, a property unique to this class, which
may be particularly relevant for patients with congestive HF
and interstitial oedema [72]. This differs from the drastic re-
duction in intravascular volume observed with loop diuretics,
which may lead to compensatory mechanisms and neurohor-
monal activation, associated with deleterious effects [76].
Alternatively, a sympathoinhibitory afferent renal nerve signal
is another possible mechanism to explain the absence of
SGLT2i activation on the sympathetic nervous system, typi-
cally activated with diuretic therapies [77]. Other differences
between SLGT2i and traditional diuretics include their urico-
suric effect [78], as well as their ability to improve endothelial
function and aortic stiffness [79–81].
Other Proposed Mechanisms
Multiple other mechanisms have been proposed to explain
the early cardio-renal benefits of SGLT2i, including hy-
potheses that rely on leptin, calcium-calmodulin inhibi-
tion, visceral adipose tissue loss and direct vascular (arte-
rial rigidity and central pressure) effects. The effect of
SGLT2i on the secretion of leptin (which contributes to
the retention of sodium and to the cardiac and renal fibro-
sis present in patients with obesity-related HFpEF) may
reduce Na+ retention and the accumulation of visceral
adipose tissue, namely epicardial fat, and thus ameliorate
the effects of systemic inflammation on the vasculature
and visceral organs [82, 83]. The recently published
EMPA-HEART CardioLink-6 trial [84] added information
to the SGLT2i CVOTs, with the inclusion of imaging
parameters evaluations. EMPA-HEART aimed to deter-
mine whether the CV benefits of SGLT2i could be sec-
ondary to a reduction in LV mass, an important and inde-
pendent predictor of MI, HF and mortality. Individuals
with T2D, coronary artery disease and a normal LV mass
index (LVMi), representative of the EMPA-REG
OUTCOME cohort, were included. After six months,
there was a significant reduction in LVMi (measured by
cardiac magnetic resonance imaging) associated with
empagliflozin [84]. Importantly, the observed reduction
in LVMi appeared to occur without reductions in LV vol-
umes, thus reflecting an overall reduction in LV wall
thickness, with a greater magnitude of regression ob-
served in patients with higher LVMi at baseline.
However, the mechanisms behind the reduction in wall
thickness remain to be elucidated, possibly relating to
changes in interstitial water content or reduced cardio-
myocyte mass. Other evidence from small studies


























































































































































































































































































































































































































































































vessels. P2059. ESC Congress 2019. 31 August—04
September 2019, Paris, France) showed that SGLT2i in-
duces a decrease in atrial volume and an improvement in
diastolic function beyond reverse remodelling [85].
Key translational mechanisms on CV physiology which
are currently in need for further data with SGLT2i are listed
in Table 4.
In conclusion, the various described hypotheses and mech-
anisms are not mutually exclusive and may all play a part in
the observed cardio-renal outcomes with SGLT2i.Most likely,
the hemodynamic, metabolic and tissue/cellular mechanisms
work synergistically in promoting the observed benefits.
The ongoing mechanistic trials being conducted mostly in
HF populations should be able to shed more light on the
SGLT2i effects in myocardial bioenergetics, biomarkers and
remodelling parameters (Table 5) [53, 86–89]. In addition, the
ongoing trials evaluating functional capacity and quality of
life (QoL), including both HFrEF and HFpEF patients
(Table 3) [39, 40] should bring further insights to guide clin-
ical practice.
Fig. 1 Overview of postulated cardio-renal SGLT2i translational
mechanisms and observed clinical outcomes. Abbreviations: ATP,
adenosine triphosphate; CO, cardiac output; GFR, glomerular filtration
rate; BP, blood pressure; EPO, erythropoietin; Glu, glucose; HCT,
haematocrit; MCU, mitochondrial calcium uniporter; Na+, sodium;
Ca2+, calcium; NHE; sodium hydrogen exchanger; NHE1 sodium-
hydrogen exchanger 1; NHE3, sodium-hydrogen exchanger 3; SCD,
sudden cardiac death; SGLT2i, sodium-glucose co-transporter 2
inhibitor; SNS, sympathetic nervous system; TGF, tubuloglomerular
feedback; LV, left ventricle; LVM, left ventricle mass; O2, oxygen;
RBC Hg, red blood cell haemoglobin; HIFs, hypoxia inducible factors;
SCD, sudden cardiac death; CAMKII, calcium/calmodulin-dependent
protein kinase II (adapted from refs. 46; 70; 71; 73; 75; 80; Verma A, et
al. J Am Coll Cardiol.. 2018; doi: https://doi.org/10.1016/j.jacc.2017.12.
034.; Arjun S, et al. Cardiovasc Res. 2019; doi: https://doi.org/10.1093/
cvr/cvz105.; Mazer CD, et al. Circulation. 2019; doi: https://doi.org/10.
1161/CIRCULATIONAHA.119.044235.; Ottolia M, et al. J Mol Cell
Cardiol. 2013; doi: https://doi.org/10.1016/j.yjmcc.2013.06.001.)
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Practical Considerations for SGLT2i
Management in T2D Patients with HF
SGLT2i Safety Profile
SGLT2i generally have a favourable efficacy and safety pro-
file. The recommended doses for the different SGLT2i are
reviewed in Supplementary table 1.
Genital mycotic infections are the most frequent AE report-
ed, as well as an increase in urinary tract infections, although
the later with no statistically significant differences compared
with placebo. Other safety issues such as bone fractures and
peripheral amputations have only been observed in one clini-
cal trial with canagliflozin [21]. A number of rare AEs have
been reported, including ketoacidosis and Fournier’s gan-
grene, which have led to specific warnings by regulatory
agencies. Nevertheless, there are specific measures that can
be previously assured to prevent and to manage these events
[90] (Supplementary table 2).
Special Considerations for Management of HF
Therapies and SGLT2i
According to the 2016 ESC HF Guidelines, empagliflozin
should be considered in T2D patients to delay or prevent
the onset of HF and prolong life, as a class IIA, level B
recommendation [1]. In the recent expert consensus up-
date from the Heart Failure Association (HFA) of the
ESC [91], it is recommended that dapagliflozin and
canagliflozin should also be considered in T2D patients
with established CVD or high CV risk to prevent or delay
the onset of HF and HHF. These documents, however, do
not specif ical ly recommended dapaglif lozin and
canagliflozin to prolong life, in alignment with the recent
ESC/EASD Guidelines for diabetes and pre-diabetes,
where prognostic recommendations are reserved to
empagliflozin based on CVOT data. Although in the
HFA expert consensus, no specific recommendations for
the use of SGLT2i could be made for patients with
established HF, some practical considerations were
highlighted. Upon initiation of an SGLT2i, an initial
“dip” in eGFR can be noted in some patients (an average
decrease of 3–5 mL/min), suggested as a positive marker
for long-term preservation of renal function [91, 92]. This
remains to be confirmed specifically in HF patients with
or without T2D.
The observed effects of SGLT2i in eGFR may be sim-
ilar to the effect noted upon initiation of angiotensin-
converting enzyme inhibitors (ACEi) or angiotensin re-
ceptor blockers (ARB) therapy, and therefore caution
may be recommended upon concomitant initiation of
SGLT2i and renin-angiotensin-aldosterone system
(RAAS) modulating therapies. The long-term renal pres-
ervation with both classes, however, may be synergistic
considering their complementary mechanisms. Similarly,
as most HF patients are managed with loop diuretics for
congestion, adjustments to baseline diuretic therapy may
be necessary upon SGLT2i initiation, based on adequate
volume assessment and definition of volume status.
Temporary discontinuation of SGLT2i and/or diuretic
agents may be required to manage clinical hypovolemia
and ketoacidosis (Supplementary table 2) [91]. Regarding
the management of diuretics in HF, the HFA has recently
published a position statement [93]. SGLT2i are described
as “other potential agents” and recommended as third-line
therapy in acute congestive HF for the management of
diuretic resistance [93]. Importantly, no specific recom-
mendations are considered for the concomitant use of
SGLT2i and other diuretics in the ambulatory chronic
HF setting, where SGLT2i therapy will most often be
implemented [94]. It is worthwhile noting that the elec-
trolyte disturbances and renal deterioration associated
with traditional diuretic agents used in HF management
are not observed with SGLT2i, which would facilitate
clinical management.
Another challenge in the management of HF patients is the
treatment-associated or underlying progression of disease-
associated hypotension. As most disease-modifying HF ther-
apies reduce BP, the addition of SGLT2i therapy (average BP
reduction of 3–5mmHg) should be implemented with caution,
particularly in patients with lower baseline BP. The strategy of
pre-emptively reducing doses of non-disease-modifying ther-
apies, such as loop diuretics, may allow for a safer introduc-
tion of SGLT2i without additive hypotension or dehydration,
as is currently recommended for achieving target doses of
disease-modifying agents. As previously highlighted, most
patients in the DAPA-HF trial were well treated with back-
ground HF therapies (including over 93% on diuretics) and no
mandatory adjustments to baseline therapy were required by
protocol; unexpectedly, the addition of dapagliflozin demon-
strated tolerability similar to placebo.
Table 4 Key translational mechanisms in need for further data with
SGLT2i
▪ Serum cardiac and renal biomarkers (e.g. NT-proBNP*, Gal-3, soluble
ST2, other)
▪ Electrophysiological mechanisms
▪ Effects on sympathetic nervous system
▪ Effects on neurohormonal responses
▪ Effects of uric acid reduction
*iSGLT2 effects on NT-proBNP levels have been contradictory and re-
quire further confirmation in large RCTs of HF populations
Abbreviations: NT-proBNP, N-terminal pro–B-type natriuretic peptide;

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Considerations for Management of Antidiabetic
Agents in Patients with HF
According to the 2016 ESCHFGuidelines, glycaemic control
should be implemented in a gradual and moderate manner,
and metformin is recommended as the first-line oral
hypoglycaemic drug for HF patients [1]. Considering this doc-
ument, as well as more recent evidence and recommendations
from the American Heart Association scientific statement on
T2D and HF [95], in addition to the 2019 ESC/EASD diabetes
guidelines [32], Table 6 summarizes the circumstances to
consider when selecting and using antidiabetic agents in pa-
tients with HF.
Unmet Medical Needs and Conclusions
Despite the close pathophysiological relation between T2D
and HF, cardiovascular outcome trials with SGLT2i were not
designed to test their efficacy and safety, specifically in HF
patients. Only a small proportion of patients in the EMPA-
REG OUTCOME trial, CANVAS program and DECLARE-
Table 6 Considerations for the
management of glucose-lowering
medications in patients with HF
(adapted from refs. 1, 32, 90)
Antidiabetic agent Considerations for management of diabetes in HF patients
Metformin Safe to use at all stages of HF in patients with preserved or moderately
reduced renal function (GFR > 30 mL/min).
Lower risk of death and HHF compared with sulphonylureas and
insulin.
Should be discontinued in patients presenting acute conditions
associated with lactic acidosis (e.g. cardiogenic or distributive
shock).
Sulphonylurea Limited data concerning the development of HF in individuals with
DM.
Effects on HF outcomes have been inconsistent.
Should be used with caution.
Insulin Associated to weight gain and risk of hypoglycaemia.
May exacerbate fluid retention, leading to HF worsening.
Should be used with caution; close monitoring.
Thiazolidinediones (glitazones) Cause sodium and water retention.
Increased risk of worsening HF and rates of HF hospitalization in
individuals with DM without HF.
Not recommended in patients with symptomatic HF, or at high risk for
developing HF.
Long-acting glucagon-like peptide 1
receptor agonists (GLP-1)
Low risk of hypoglycaemia.
Safe to use and improve glycaemic indices, but not beneficial in
preventing HF in patients at risk.
Neutral effect on HHF.
Use may be considered.
Dipeptidylpeptidase-4 inhibitors
(DPP4is; gliptins)
Improved glycaemic indices but no evidence on cardiovascular
benefit.
Can increase the risk of HHF in patients with DM at high
cardiovascular risk (i.e. saxagliptin, possible with alogliptin).
Increases in LV volumes were observed with vildagliptin. Neutral
effects for sitagliptin and linagliptin.
Should not be considered in patients with HF, or at high risk for
developing HF.
Sodium-glucose co-transporter type 2
inhibitors (SGLT2i)
First class of glucose-lowering agents to demonstrate HF
hospitalization risk reduction in patients with DM.
Recommended for patients with T2D to reduce HF risk (class IA
recommendation).
Promising for treatment of established HF in patients with and
without DM.
Abbreviations: DM, diabetes mellitus; GFR, glomerular filtration rate; HF, heart failure; HHF, hospitalization for
heart failure; LV, left ventricular; T2D, type 2 diabetes mellitus
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TIMI 58 trial had a diagnosis of HF at baseline (and in those
who had, the HF phenotype was not initially characterized).
DAPA-HF was the first in class RCT to demonstrate a signif-
icant impact of an SGLT2i vs. placebo, on top of optimal
medical therapy, in terms of morbidity and mortality in pa-
tients with HFrEF, irrespective of the presence of T2D [35,
38].
Similarly, the smaller DEFINE-HF trial supported these
results by showing beneficial effects of dapagliflozin on HF-
related QoL, and symptoms in HFrEF patients [40], and
dapagliflozin has now been given a “fast track” status by the
FDA for a proposed indication to reduce CV death or wors-
ening HF.
The results from ongoing SGLT2i HF-dedicated out-
comes trials are expected to lead to a growing potential
for SGLT2i use in HF clinical practice (in the same way
that the EMPA-REG OUTCOME trial drove a major
shift in T2D management) and will answer the remaining
questions of whether the results observed in DAPA-HF
extend to other SGLT2i, and if the beneficial effects also
include the HFpEF population.
Additional potential usage of SGLT2i may be anticipated
for the treatment of acute HF (AHF), which is the major cause
of HHF, and for which there are no currently available thera-
pies that improve clinical outcomes [96]. The EMPA Acute
Heart Failure, EMPAG-HF and EMPULSE trials are under-
way to study the effects of SGLT2i on clinical outcomes in the
AHF popula t ion (Clin ica lTr ia ls .gov Ident i f ie rs :
NCT03554200, NCT04049045 and NCT04157751,
respectively), while the EMPA-RESPONSE study has been
published recently [97].
Another limitation of the RCT evidence with SGLT2i is
that the reported trials were designed to test CV outcomes,
but not SGLT2i CV actions, for which mechanistic clinical
trials are currently underway (Table 5). The results of ongoing
trials are eagerly awaited by the scientific HF community,
especially considering the growing number of HF patients
worldwide.
In summary, the evidence to date tells us that SGLT2i offer
cardioprotection for HF patients (particularly those with
HFrEF) and also to those at risk for developing HF, benefits
that appear to be independent of glycaemic control, and that
are observed in populations with and without T2D. The mech-
anisms underlying this protection can act in various ways and
be complementary or synergistic.
Deepening this knowledge may help to identify more
targeted therapies in the future, according to the patients’ over-
all CV and HF profile.
Undoubtedly, a new chapter of this history has begun.
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